All News

Here's what you can be thankful for...

The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.

I used my tools as a psychotherapist after being faced with my own cancer diagnosis.

The FDA has granted priority review for the Padcev-Keytruda combination in untreated patients with metastatic bladder cancer, according to a news release.

A recent study showed that incorporating immunotherapy checkpoint blockade into treatment before and after surgery can increase treatment-related side effects.

The recent FDA approval of the next-generation tyrosine kinase inhibitor Augtyro provides patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer another treatment option when the disease becomes resistant to other therapies.

After all these blogs, there’s still one side effect I haven’t talked about.

Results from a four-year follow-up of a phase 3 trial determined that the combination of Imbruvica and Venclexta provided benefits for untreated patients with CLL.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

Cervical cancer survival and Cervivor ambassador Kate Weissman provides advice on conversations patients with cervical cancer should be having with their care teams.

The scar tissue surrounding pancreatic cancer may offer prognostic insight — and potential new treatment strategies — for patients with pancreatic cancer.

I didn't know that a side effect of bone strengtheners could be jawbone detachment.

Zotatifin plus Faslodex and Verzenio was granted as a Fast Track Designation for the treatment of ER-positive, HER2-negative advanced or metastatic breast cancer.

The Food and Drug Administration approved Jaypirca for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received two or more lines of therapy.

The Food and Drug Administration granted a Breakthrough Therapy Designation to Epkinly to treat patients with relapsed or refractory follicular lymphoma.

The Truqap-Faslodex treatment combination offers “more options” for some patients with HR-positive, HER2-negative breast cancer, an expert told CURE®.

If you have scanxiety, you aren't alone.

As Shannen Doherty revealed her cancer diagnoses and upcoming podcast and a woman with breast cancer completed her bucket list, here is what’s happening in the oncology space this week.

Treatment with Imfinzi for patients with advanced or metastatic NSCLC and limited physical performance status offered beneficial overall survival and maintained quality of life.

Analysis of molecular subtypes of muscle-invasive bladder cancer can predict if a tumor is likely to respond to chemotherapy before surgery but is not associated with differences in survival.

Although patient-facing AI could be more convenient in some settings, researchers delved into the ethical challenges and threats to patient dignity.

An expert discusses the FDA’s investigation into the possible association between CAR-T cell therapy and secondary T-cell malignancies.

As we all know, added stress for patients with cancer is never a good thing.

Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’

A recent study revealed that patients with recurrent or metastatic non-small cell lung cancer tended to have better overall survival compared with those diagnosed with stage 4 disease.

Looking back, here’s what I would tell myself shortly after being diagnosed with cancer.

Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).

The FDA announced rare instances of secondary diseases or cancers from CAR-T cell therapy, though this is not the first time that oncology treatments have been associated with secondary diseases.